Clinical spectrum and hormonal profile of patients with non-inflammatory benign breast disorders: a cross-sectional study

Asmita Chopra; Shaji Thomas; Kartikeya Sharma; Amita Yadav; Manjula Jain; Rama Anand

doi:10.18203/2349-2902.isj20232981

Authors

Asmita Chopra Department of Surgery, Lady Hardinge Medical College, New Delhi, India
Shaji Thomas Department of Surgery, Lady Hardinge Medical College, New Delhi, India
Kartikeya Sharma Department of Surgery, Lady Hardinge Medical College, New Delhi, India
Amita Yadav Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India
Manjula Jain Department of Pathology, Lady Hardinge Medical College, New Delhi, India
Rama Anand Department of Radiology, Lady Hardinge Medical College, New Delhi, India

DOI:

https://doi.org/10.18203/2349-2902.isj20232981

Keywords:

Breast, Fibroadenoma, Mastitis, Steroid hormone, BBD, Fibrocystic breast disease

Abstract

Background: Benign breast disorders (BBD) are one of the most common problems seen in women. Since development of the breast is under the influence of various hormones, this study was done to document the clinical spectrum of females with BBD, and to understand if any association exists between serum levels of various hormones and BBD.

Methods: This was a cross sectional study of 134 patients who presented to the surgical OPD with non-inflammatory BBD. These patients were evaluated for serum levels of 8 hormones-estrogen, progesterone, follicle stimulating hormone (FSH), luteinising hormone (LH), prolactin, thyroid stimulating hormone (TSH), testosterone and prostate specific antigen (PSA). The levels of these hormones were correlated with the type of BBD.

Results: Breast pain was the most common presenting complaint (67.16%), followed by breast lump (51.49%). Most patients were diagnosed as proliferative BBD (50%) followed by mastalgia (32.8%) and non-proliferative BBD (17.2%), 36.57% patients had fibroadenoma. The 73.88% of patients showed abnormal serum levels of at least one of the hormones. Most common abnormalities were significantly detectable levels of serum PSA (51.4%), and decreased levels of serum testosterone (20.8%). Among the rest, TSH was raised in 9.7%, estrogen was raised in 9.7%, FSH was raised in 8.9%, prolactin was raised in 8.9%, LH was raised in 6.7% and progesterone was raised in 2.9%.

Conclusions: Our study suggests that abnormality in various hormones (seen in 73.88% of our patients) could be responsible for development of BBD. The interplay of these hormones on aberrations in breast development and involution is unclear and warrants further studies on larger populations.

Metrics

Metrics Loading ...

References

Hughes LE, Mansel RE, Webster DJT. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet. 1987;2(8571):1316-9.

Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am. 2002;29(1):1-20.

Wilson JD. Sexual differentiation. Annu Rev Physiol. 1978;40:279-306.

Sangma MBM, Panda K, Dasiah S. A Clinico-Pathological Study on Benign Breast Diseases. J Clin Diagn Res. 2013;7(3):503-6.

Kaur N, Agarwal N, Panwar P, Mishra K. Clinicopathologic Proﬁle of Benign Breast Conditions in Indian Women: Prospective Study Based on Aberrations of Normal Development and Involution Classiﬁcation. World J Surg. 2012;36(9):2252-8.

Samoli E, Trichopoulos D, Lagiou A, Zourna P, Georgila C, Minaki P et al. The hormonal profile of benign breast disease. Br J Cancer. 2013;108(1):199-204.

Okoth C, Galukande M, Jombwe J, Wamala D. Benign proliferative breast disease among female patients at a sub Saharan Africa tertiary hospital: a cross sectional study. BMC Surg. 2013;13:9.

Sasaki Y, Miki Y, Hirakawa H, Onodera Y, Takagi K, Akahira J et al. Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: comparison with normal breast and breast carcinoma. Cancer Sci. 2010;101(10):2286-92.

Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008;100(8):563-71.

Sitruk-Ware R, Clair F, Sterkers N, Ulmann A, Mauvais-Jarvis P. Prolactin secretion in benign breast diseases. Gynecol Endocrinol. 1987;1(2):195-200.

Mancini A, Di Pietro C, De Marinis L, Rossi S, Lombardi CP, Iacona T et al. Endocrine evaluation of patients with benign lumps of the breast. Cancer Detect Prev. 1992;16(1):27-30.

Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2337-43.

Garde SV, Sheth AR, Joseph R, Panchal CJ, Chinoy RF, Sheth NA. Occurrence and de novo biosynthesis of follicle stimulating hormone (FSH) in benign and malignant conditions of human breast. Cancer Lett. 1993;75(1):1-9.

Mancini A, Di Pietro C, De Marinis L, Rossi S, Lombardi CP, Bellantone R et al. Endocrine status in patients with mammary gland diseases: correlation between steroid hormones and sex steroid binding globulin. Gynecol Endocrinol. 1991;5(2):101-8.

Peters F, Schuth W, Scheurich B, Breckwoldt M. Serum -prolactin levels in patients with fibrocystic breast disease. Obstet Gynecol. 1984;64(3):381-5.

Watt-Boolsen S, Eskildsen PC, Blaehr H. Release of prolactin, thyrotropin, and growth hormone in women with cyclical mastalgia and fibrocystic disease of the breast. Cancer. 1985;56(3):500-2.

Mansel RE, Preece PE, Hughes LE. A double-blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg. 1978;65(10):724-7.

Nazli K, Syed S, Mahmood MR, Ansari F. Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J Clin Pract. 1989;43(9):322-7.

Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab. 2010;95(1):271-9.

Nicol M, Willis C, Yiangou C, Sinnett D, Shousha S. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: a detailed study of 153 consecutive cases. Breast J. 2002;8(5):281-5.

Rose LI, Underwood RH, Dunning MT, Williams GH, Pinkus GS. Testosterone metabolism in benign and malignant breast lesions. Cancer. 1975;36(2):399-403.

Mady EA. Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol. 2000;75(4-5):323-8.

Bhargav PR, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33(10):2087-93.

Estes NC. Mastodynia due to fibrocystic disease of the breast controlled with thyroid hormone. Am J Surg. 1981;142(6):764-6.

Nariţa D, Raica M, Anghel A, Suciu C, Cîmpean A. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol. 2005;46(1):41-5.

Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171-8.